Forum Financial Management LP Sells 1,935 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Forum Financial Management LP reduced its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 10.7% during the second quarter, Holdings Channel.com reports. The institutional investor owned 16,183 shares of the company’s stock after selling 1,935 shares during the quarter. Forum Financial Management LP’s holdings in Teva Pharmaceutical Industries were worth $271,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Bourgeon Capital Management LLC grew its position in shares of Teva Pharmaceutical Industries by 100.7% in the 2nd quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company’s stock worth $12,134,000 after buying an additional 363,252 shares during the last quarter. Amundi grew its position in shares of Teva Pharmaceutical Industries by 18.5% in the 1st quarter. Amundi now owns 678,758 shares of the company’s stock worth $10,080,000 after buying an additional 105,846 shares during the last quarter. IFM Investors Pty Ltd grew its position in shares of Teva Pharmaceutical Industries by 9.4% in the 2nd quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company’s stock worth $3,797,000 after buying an additional 19,447 shares during the last quarter. Jump Financial LLC grew its position in shares of Teva Pharmaceutical Industries by 172.1% in the 1st quarter. Jump Financial LLC now owns 1,325,526 shares of the company’s stock worth $20,373,000 after buying an additional 838,423 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its position in shares of Teva Pharmaceutical Industries by 5.7% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company’s stock worth $38,487,000 after buying an additional 134,705 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, insider Placid Jover sold 6,053 shares of the business’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the transaction, the insider owned 6,774 shares in the company, valued at $102,693.84. The trade was a 47.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Eric A. Hughes sold 52,742 shares of the business’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Stock Down 0.4%

Shares of NYSE:TEVA opened at $18.95 on Monday. The stock has a fifty day simple moving average of $19.08 and a two-hundred day simple moving average of $17.31. The stock has a market capitalization of $21.73 billion, a price-to-earnings ratio of -118.41, a PEG ratio of 1.04 and a beta of 0.71. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $22.80. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The business had revenue of $4.18 billion during the quarter, compared to analysts’ expectations of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm’s quarterly revenue was up .3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on TEVA shares. JPMorgan Chase & Co. lifted their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Friday, October 3rd. UBS Group lifted their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Friday. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $25.57.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.